ACHN News 10.89 10/17/2014 04:22:59 Achillion Pharmaceuticals

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
Achillion Pharmaceuticals (ACHN) 10.89 $ACHN

Nasdaq stocks posting largest percentage increases
AP - Thu Oct 09, 5:02PM CDT
NEW YORK (AP) — A look at the 10 biggest percentage gainers on Nasdaq at the close of trading:
SSRI: 5.84 (+0.10), BRID: 8.49 (unch), RENT: 72.90 (-1.00), JAXB: 11.82 (+0.62), RDUS: 18.74 (+0.29), DRIV: 16.76 (+0.16), OBCI: 4.26 (+0.17), SSO.TO: 6.56 (+0.10), ACHN: 10.89 (+0.76), AUXL: 30.35 (-0.06), LAKE: 20.69 (-2.91), GTIV: 19.42 (+0.07)

November 28th Options Now Available For Achillion Pharmaceuticals (ACHN)
DividendChannel.com - Thu Oct 09, 10:04AM CDT
Investors in Achillion Pharmaceuticals Inc. saw new options become available today, for the November 28th expiration.
ACHN: 10.89 (+0.76)

Achillion to Present Updated Clinical HCV Data on ACH-3102 and Preclinical Profile of ACH-3422 at the American Association for the Study of Liver Diseases (AASLD) Annual Meeting
GlobeNewswire - Wed Oct 08, 9:23AM CDT
- Late breaker poster presentation will feature updated SVR results from the Phase 2 trial of ACH-3102, NS5A inhibitor, plus sofosbuvir for the eight-week treatment of genotype 1 HCV -
ACHN: 10.89 (+0.76)

Biotech Stock Mailbag: Seattle Genetics, Achillion, Catalyst Pharma
at The Street - Fri Oct 03, 8:41AM CDT
Biotech columnist Adam Feuerstein answers readers' questions about health care.
JNJ: 96.78 (-1.43), SGEN: 34.73 (+1.40), CPRX: 2.43 (-0.01), ACHN: 10.89 (+0.76), SNSS: 1.36 (+0.12), BMY: 49.22 (+0.26)

Did Achillion Pharmaceuticals, Inc. Get Left Out in the M&A Cold?
Todd Campbell, The Motley Fool - Motley Fool - Wed Oct 01, 11:37AM CDT
Source: Achillion Pharmaceuticals. Achillion investors are probably shaking their heads wondering what's wrong with their company following  Johnson & Johnson 's  acquisition of the privately held Alios for $1.7 billion this week. On the...
JNJ: 96.78 (-1.43), GILD: 96.88 (+0.72), ACHN: 10.89 (+0.76)

J&J Buying Alios, Going Up Against Gilead
at Investor's Business Daily - Tue Sep 30, 11:02AM CDT
Medical giant Johnson & Johnson agreed to buy privately held biotech Alios BioPharma for $1.75 billion Tuesday, advancing its presence in viral diseases. Johnson & Johnson (JNJ) stock was up a fraction in morning trading on the stock market today. In...
JNJ: 96.78 (-1.43), VRTX: 101.26 (+0.16), GILD: 96.88 (+0.72), ACHN: 10.89 (+0.76), MRK: 53.43 (-1.30)

Why J&J Expands Antiviral Franchise but Doesn't Buy Achillion, Novavax
at The Street - Tue Sep 30, 8:49AM CDT
What are the motivations behind significant takeovers, like J&J's takeover of Alios Biopharma? And why have companies like Achillion and Novavax been passed over?
JNJ: 96.78 (-1.43), VRTX: 101.26 (+0.16), GILD: 96.88 (+0.72), NVAX: 5.16 (+0.47), ACHN: 10.89 (+0.76)

Critical Alerts For Achillion Pharmaceuticals, Dreamworks Animation, SunEdison, El Pollo Loco and Whole Foods Market Released By InvestorsObserver
PR Newswire - Tue Sep 30, 8:31AM CDT
InvestorsObserver issues critical PriceWatch Alerts for ACHN, DWA, SUNE, LOCO and WFM.
WFM: 36.87 (-0.05), SUNE: 15.57 (+0.46), ACHN: 10.89 (+0.76), LOCO: 33.45 (-0.12), DWA: 20.28 (-0.55)

The 5 Best Biotech Stocks in 2014...so far
Todd Campbell, The Motley Fool - Motley Fool - Fri Sep 26, 7:35AM CDT
Since the quarter is wrapping up and investors are considering their game plan heading into year-end, let's look at biotech's biggest winners for the year, why they've rallied, and whether they make sense for your portfolio . Specifically, let's...
GILD: 96.88 (+0.72), ACHN: 10.89 (+0.76), RCPT: 61.11 (-0.96), PTCT: 37.55 (+0.48), ICPT: 216.64 (+18.56), PBYI: 221.41 (+6.22)

Biotech Stocks Technical Data - Medivation, Galectin Therapeutics, Ironwood Pharma, Achillion Pharma, and PDL BioPharma
PR Newswire - Tue Sep 16, 8:05AM CDT
The US markets on Monday, September 15 2014, ended on a mixed note as the Dow Jones Industrial Average finished at 17,031.14, up 0.26% and the NASDAQ Composite closed at 4,518.90, down 1.07%. The S&P 500 finished the session 0.07% lower at 1,984.13. During the trading session, seven out of ten sectors finished on a higher note. The S&P 500 Health Care Sector Index ended the day at 734.33, down 0.32%, whereas the index has gained 6.67% in the previous three months. Investor-Edge has initiated coverage on the following equities: Medivation Inc. (NASDAQ: MDVN), Galectin Therapeutics Inc. (NASDAQ: GALT), Ironwood Pharmaceuticals Inc. (NASDAQ: IRWD), Achillion Pharmaceuticals Inc. (NASDAQ: ACHN), and PDL BioPharma Inc. (NASDAQ: PDLI). Free research on these five companies can be accessed at:
MDVN: 92.54 (+2.91), IRWD: 12.88 (-0.47), ACHN: 10.89 (+0.76), GALT: 5.17 (+0.29), PDLI: 8.13 (+0.50)

ACHN, IBIO, CRAY, IBCA, QLTY, PIY Are Seasonally Ripe To Go Down In the Next Five Weeks
M2 - Tue Sep 16, 6:08AM CDT
BUYINS.NET / www.squeezetrigger.com is monitoring the Seasonality of Achillion Pharmaceuticals Inc (NASDAQ:ACHN), Ibio Inc (NYSE:IBIO), Cray Inc (NASDAQ:CRAY), Intervest Bancshares Corp (NASDAQ:IBCA), Quality Distribution Inc (NASDAQ:QLTY), Preferredplus Trust Series Czn 1 (NYSE IY) and each have a high seasonal probability to go Down in the next weeks. By identifying stocks that are poised to go up or down based on seasonal tendencies, traders can increase their odds of making money. SqueezeTrigger.com is able to analyze over 20 years of data in less than 1 second for any stock in the market and determine if the stock has a long or short seasonal bias, how many trading days the move is expected to last, the probability of that move and the percentage move the stock is expected to make based on the seasonal bias. The technology used to generate these predictions is available for a low monthly fee at:
PIY: 25.93 (+0.38), QLTY: 11.20 (+0.10), ACHN: 10.89 (+0.76), IBIO: 1.89 (+0.50), IBCA: 9.62 (+0.07), CRAY: 27.52 (+2.17)

'Fast Money' Recap: How Alibaba Is Hitting Momentum Stocks
at The Street - Tue Sep 16, 4:00AM CDT
The trading panel discussed Chinese stocks, Apple's new phone and whether Darden shares are worth buying.
TSLA: 226.35 (-3.35), XBI: 156.59 (+4.37), IBB: 260.98 (+4.51), JBLU: 11.22 (+0.92), DEO: 110.14 (+0.37), NOK: 7.80 (+0.03), YHOO: 38.12 (+0.30), EBAY: 47.88 (-2.36), PLCE: 48.23 (+0.20), TWTR: 48.23 (-1.76), MSFT: 42.74 (-0.48), AAPL: 96.26 (-1.28), REGN: 340.71 (+5.96), AMZN: 302.86 (-3.11), ABX: 13.78 (+0.23), NADL: 5.60 (+0.06), DRI: 48.36 (+0.12), CELG: 86.38 (-0.17), AA: 14.60 (+0.10), BIDU: 211.22 (+5.49), TSO: 59.81 (+1.17), GILD: 96.88 (+0.72), ACHN: 10.89 (+0.76), IWM: 107.80 (+1.20), BF.B: 83.84 (+0.23), CRM: 53.87 (+0.78)

Critical Alerts For Achillion Pharmaceuticals, LightInTheBox, VoxelJet, Whole Foods Market and Disney Released By InvestorsObserver
PR Newswire - Mon Sep 15, 8:31AM CDT
InvestorsObserver issues critical PriceWatch Alerts for ACHN, LITB, VJET, WFM and DIS.
WFM: 36.87 (-0.05), VJET: 13.39 (+0.78), ACHN: 10.89 (+0.76), DIS: 81.74 (-0.34), LITB: 6.38 (+0.19)

Jim Cramer's 'Mad Money' Recap: Enjoy This Bull Market While It Lasts
at The Street - Thu Sep 11, 6:47PM CDT
As long as it's here, good things are happening every day, Cramer says.
SD: 4.57 (+0.03), RH: 76.42 (+1.44), RAX: 34.69 (-0.35), EMN: 74.34 (+0.87), OKE: 56.55 (+2.07), KORS: 72.07 (+0.65), ATK: 127.46 (+3.46), CNVR: 34.10 (+0.56), SBUX: 72.64 (+0.26), SON: 38.44 (+0.71), ACAD: 25.29 (+0.18), COH: 35.12 (-0.42), FSLR: 54.22 (+0.98), ISIS: 40.56 (+1.59), ACHN: 10.89 (+0.76), JE: 4.46 (+0.12), MTN: 82.75 (+0.62), AIG: 49.40 (-0.29), KATE: 25.52 (+0.22), TWTR: 48.23 (-1.76), TASR: 14.97 (+0.28), SWHC: 9.86 (+0.33)

Can the Rally in Achillion (ACHN) Shares Continue? - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Wed Sep 10, 9:58AM CDT
Can the Rally in Achillion (ACHN) Shares Continue?
ACHN: 10.89 (+0.76)

Technical Updates, Operational Milestones, Product Upgrades, and Energy Saving Programs - Research Reports on Achillion, DE, Honeywell, Lockheed Martin and L-3 Communications
PR Newswire - Tue Sep 09, 7:35AM CDT
Today, Analysts Review released its research reports regarding Achillion Pharmaceuticals, Inc. (NASDAQ: ACHN), Deere & Company (NYSE: DE), Honeywell International Inc. (NYSE: HON), Lockheed Martin Corporation (NYSE: LMT) and L-3 Communications Holdings Inc. (NYSE: LLL). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/6311-100free.
LMT: 174.72 (-0.47), HON: 86.39 (+1.28), ACHN: 10.89 (+0.76), DE: 84.12 (-0.81), LLL: 109.23 (+0.14)

Most active Nasdaq-traded stocks
AP - Fri Sep 05, 2:45PM CDT
NEW YORK (AP) — A look at Nasdaq 10 most-active stocks at 1 p.m.:
EBAY: 47.88 (-2.36), GILD: 96.88 (+0.72), FB: 72.63 (-0.58), ACHN: 10.89 (+0.76), MSFT: 42.74 (-0.48), INTC: 30.85 (-0.42), AAPL: 96.26 (-1.28), CSCO: 22.82 (-0.14)

Biotech Stock Mailbag: Achillion, Ariad Revisited, Endocyte
at The Street - Fri Sep 05, 7:55AM CDT
Biotech columnist Adam Feuerstein answers readers' questions about health care.
MDVN: 92.54 (+2.91), ECYT: 5.85 (+0.17), ACHN: 10.89 (+0.76), ARIA: 5.36 (-0.12), EXEL: 1.62 (+0.07)
Scroll down for more posts ▼

Top 10 Most Recent News Articles

Vertex Extends Genomics Pact With $220M in Potential

Updated Category News Views 147

Eight years is long enough to separate a useful science partner from a glossy slide deck, and Vertex’s decision to add four more years with Genomics deserves attention. This is not a splashy acquisition, nor is it a clean revenue number investors can plug into next quarter’s model. It is a deeper commitment to the slow, expensive, wonderfully unforgiving business of...

Continue Reading
Early Dog Guarding Signs Matter Before a Sudden Growl

Updated Category News Views 92

A bowl, a chewed-up toy, or a patch of couch can turn tense in a heartbeat. That is why the useful part of Brian Manning's guidance is not some fantasy of making every dog endlessly tolerant; it is learning to notice discomfort while there is still room to back off safely. For anybody watching the pet-care and behavior-training field, this is the kind of plainspoken...

Continue Reading
Humanoid Robots Need Results Before 2035 Hype Peaks

Updated Category News Views 245

A robot climbing stairs is neat; a robot finishing Tuesday’s shift is the investment case. The latest humanoid robotics forecast puts the global market at $3.07 billion in 2026, up from $2.26 billion in 2025, and projects $47.49 billion by 2035. That is a 35.59% compound annual growth rate, the kind of number that makes investors sit up straight. It also demands a...

Continue Reading
Health In Tech Brings a Tech Veteran Onto Its Board

Updated Category News Views 115

Board appointments rarely make the cash register ring, but they can tell you where management thinks the next bruises are coming from. Health In Tech has added Tim Cortes as an independent director, put him in charge of the Compensation Committee, and placed him on both the Audit and Nominating and Corporate Governance Committees. For an AI-enabled insurance technology...

Continue Reading
Misunderstood Brands Bets Small Cans Can Scale Growth

Updated Category News Views 168

A tiny cocktail can is a brutal little test of whether a spirits brand has legs. Misunderstood Brands is putting four 100mL offerings on the shelf just as its Wegmans distribution expands across the East Coast, and that combination matters more than another glossy flavor announcement. The company is trying to turn products people discovered in bars and restaurants into...

Continue Reading
Clarivate's 2026 Research List Carries a Trust Test

Updated Category News Views 254

Seven thousand ninety awards can look like a victory lap until you remember how easily raw citation counts can be gamed. Clarivate’s 2026 Highly Cited Researchers list is more interesting for its insistence on screening than for the familiar names at the top. In a research world where publication volume, self-citation and paper mills have made plenty of people...

Continue Reading
Excel Treatment Center Adds ART Trauma Therapy Option

Updated Category News Views 158

Trauma rarely arrives at an addiction program wearing a name tag. Excel Treatment Center in Dover, New Jersey, is responding to that uncomfortable reality by adding Accelerated Resolution Therapy® (ART) to the individual, group, and family therapy already available to its clients. The center says its therapists have completed ART training, and the approach is now part of...

Continue Reading
Peñoles Locks In Solar Storage for Northern Mine Loads

Updated Category News Views 54

A mine never sleeps, which is why the battery matters more than the solar-panel headline. Peñoles has signed a 20-year power-supply agreement with Atlas Renewable Energy for a Coahuila project combining 269 MWp of solar generation with battery storage. The project is slated to begin operating in the first half of 2029 and is expected to provide roughly 550 GWh a year to...

Continue Reading
Anycubic Pushes Toward a Smoother 3D Printing Ecosystem

Updated Category News Views 68

Friction Is the Enemy in Consumer 3D Printing A printer that makes a beautiful object only after three failed attempts is not a consumer product; it is a weekend argument with plastic. That is the useful lens for Anycubic's Formnext 2026 showing in Frankfurt on November 18. The company is not merely rolling out FDM and resin machines at Booth F01 in Hall 12.0. It is...

Continue Reading
Workday’s EU Cloud Move Raises the Sovereignty Bar Again

Updated Category News Views 124

Europe’s sovereignty squeeze just got a lot more concrete for Workday. The company is taking its EU Sovereign Cloud beyond the usual data-residency talking points by planning an Ireland-based operating company, European leadership, and governance intended to keep decisions on the service and customer data inside Europe. For a platform sitting underneath payroll, HR...

Continue Reading

Top 5 Most Recently Viewed Articles

Hepsiburada's Impressive Q3 2025 Performance Review

Updated Category News Views 281

Hepsiburada Reports Significant Gains in Q3 2025 Hepsiburada, officially known as D-MARKET Electronic Services & Trading (NASDAQ: HEPS), has unveiled robust financial results for the third quarter of 2025. The Turkish e-commerce giant reported an impressive increase in gross merchandise value (GMV) and revenue, highlighting the company's operational resilience in a...

Continue Reading
Fulcrum Therapeutics Faces Challenges Amid Sickle Cell Trials

Updated Category News Views 212

Market Moves and Stock Reactions So, let’s get straight to the meat of it. Fulcrum Therapeutics Inc. (NASDAQ:FULC) took a nosedive recently—down about 10%—right after they dropped the latest news on their Phase 1b trial for pociredir aimed at treating sickle cell disease. Stock fell to around $9.80, and honestly, if you're still holding shares, well, it's time to...

Continue Reading
SBM Offshore's Share Repurchase Program Insights and Updates

Updated Category News Views 215

Overview of SBM Offshore’s Share Repurchase Program SBM Offshore has recently conducted a significant share repurchase program amounting to EUR141 million (approximately US$150 million). This initiative began on April 24, 2025, and aims to reduce share capital while also supporting management and employee share programs. The program has been designed to both enhance...

Continue Reading
Plymouth Industrial REIT Responds to Acquisition Proposal

Updated Category News Views 212

Plymouth Industrial REIT Receives Unsolicited Acquisition Proposal Plymouth Industrial REIT, Inc. (NYSE: PLYM), a leader in the industrial real estate sector, recently attracted attention with an unsolicited and non-binding acquisition proposal. This proposal comes from Sixth Street Partners, LLC, and suggests a price of $24.10 per share for all outstanding shares of the...

Continue Reading
Middlefield Canadian Income PCC AGM Results Breakdown

Updated Category News Views 230

Overview of the AGM Results for Middlefield Canadian Income PCC Middlefield Canadian Income PCC (the "Company") and Middlefield Canadian Income - GBP PC (the "Cell") have recently concluded their annual general meeting, a significant event that spotlighted the Company's journey and future direction. Conducted with transparency and diligence, this meeting has underscored...

Continue Reading